Grant Announcements

Defining Clinical Endpoints in LGMD

Coalition to Cure Calpain 3 (C3) is pleased to announce that a research grant has been awarded to Dr. Nicholas Johnson, Associate Professor & Vice Chair of Research, Virginia Commonwealth University. The project is titled “Defining Clinical Endpoints in LGMD.”

What are COAs, and why do they matter to those living with LGMD?

Clinical outcome assessments (COAs) are measurements used during clinical trials to determine if an investigational drug or therapy provides benefit. As therapeutics are being developed for limb girdle muscular dystrophies (LGMDs), it is important to prepare for clinical trials by developing robust COAs that are sensitive to changes and represent aspects of the disease that are important to patients.

Dr. Johnson and colleagues recently established a Limb Girdle Muscular Dystrophy Clinical Research Network, funded by a grant from the Muscular Dystrophy Association, which brings together eight medical centers with significant expertise in LGMD research and clinical care. The current observational study will follow LGMD2A patients over a period of 12 months to establish which COAs are sensitive to normal disease progression, so that these may be used as tools during future clinical trials.

“A lack of standard COAs for LGMD2A is a barrier to therapy development for this disease. Dr. Johnson’s project will develop tools which will be used to determine if investigational drugs are effective in a clinical trial setting.”
— Jennifer Levy, Scientific Director, Coalition to Cure Calpain 3

“The development of gene replacement therapies has accelerated the need to prepare for clinical trials. We are excited to begin working with C3, the MDA, and the LGMD2A community to develop the tools necessary to test these potential treatments.”
— Dr. Nicholas Johnson

Recent Posts

  • New Research Alert! "The Energy Switch"

    A new paper, “CaMKIIβ Signaling drives expression of metabolic and stress response genes in skeletal muscle, and its loss contributes to the LGMDR1 phenotype,” was recently published in the journal Human Molecular Genetics. It was authored by a multi-institutional group led by Dr. Melissa Spencer, C3 Scientific Advisory Board Chair and Professor of Neurology and... Read More
    Jennifer Levy Research Updates

  • C3 on Capitol Hill: LGMD Day on the Hill 2026

    C3 was proudly represented in Washington, D.C. at the 2026 LGMD Day on the Hill, hosted by The Speak Foundation. C3 Advocacy Chair Melina Garza was selected as a 2026 delegate and had the privilege of leading the Texas and North Carolina delegation through a packed day of advocacy on Capitol Hill. The day began... Read More
    Michele Wrubel Advocacy